13 news items
Pharma Stock Roundup: FDA Panel Endorses LLY's Donanemab, PFE's DMD Therapy Study Fails
ABBV
AZN
LLY
14 Jun 24
characterized by chronic inflammation in the gastrointestinal tract. FG-M701, a novel TL1A inhibitor, is in pre-clinical development. These next-generation IBD
AbbVie Launches First-of-its-Kind Contest to Empower People Living with Migraine in their Careers
ABBV
6 Jun 24
.3 In the workplace specifically, findings from the Chronic Migraine Epidemiology and Outcomes (CaMEO) study, and more
RINVOQ® (upadacitinib) Now Available for Pediatric Patients Two Years and Older with Polyarticular Juvenile Idiopathic Arthritis and Psoriatic Arthritis
ABBV
4 Jun 24
lesions associated with psoriasis.4 These chronic diseases can be painful and debilitating and, if left
Silo Pharma's (NASDAQ: SILO) Promising Developments and Key Insights for Traders and Investors
ABBV
JNJ
LLY
4 Jun 24
for advancing its pipeline of treatments, including SPC-15 and other promising candidates like SP-26 for fibromyalgia and chronic pain relief, and SPC-14
AbbVie Skyrizi Gets CHMP Nod for Ulcerative Colitis in EU
ABBV
ALXO
ANVS
3 Jun 24
the drug's label in the EU. UC is a type of chronic inflammatory bowel disease that affects the colon and rectum.
AbbVie has also
jzvrnvod0dh78ueta9k5izd9zopwj3522n69mdjk95cj2mymxv97wzg0
ABBV
31 May 24
improvement,† were met1,2
UC is a chronic, idiopathic, immune-mediated inflammatory bowel disease (IBD) affecting the large
yhs8mjvq55377hs4pkroeyhjhjeilculg1z3mvf
ABBV
31 May 24
UC is a chronic, idiopathic, immune-mediated inflammatory bowel disease (IBD) affecting the large intestine. It can lead to a substantial burden
xtm1iigq8 fmefjqd39gey18jkn7g8ncdqc
ABBV
17 May 24
in inflammatory processes, is thought to be linked to a number of chronic immune-mediated diseases.3 SKYRIZI
4gpxnf v0
ABBV
25 Apr 24
.
About Atopic Dermatitis Atopic dermatitis is a chronic, relapsing inflammatory condition
brzw3 qs974vuynzaifp9
ABBV
18 Apr 24
.Have other medical conditions, including liver problems, low blood cell counts, diabetes, chronic lung disease, HIV
6zaj2h0vdofm7yj6i24gcctgvqry 3cuube3dmzt0lf
ABBV
12 Apr 24
with chronic or episodic migraine
ceqxjmk zgav0bzo7ap1ktjfe10c5te8yy1i7
ABBV
12 Apr 24
in participants with chronic or episodic migraine. The overall long-term safety results were consistent with the known safety profile of atogepant in chronic
ofz2klnqqx11wmr08w5uu4h65hfz3 i8kcpwadpvxc3oiu9b7q45o2
ABBV
12 Apr 24
extension study supports long-term safety, tolerability and efficacy of atogepant 60 mg to prevent chronic
- Prev
- 1
- Next